Biogen strikes RNAi deal with City; Aurion withdraws IPO

City will receive $46 million from Biogen under the alliance. Elsewhere, Angelini Pharma licensed a rare disease therapy and the FDA refused to review a Savara lung drug.

By BioPharma Dive staff • May 27, 2025

Patient dies in trial of Rocket gene therapy for heart condition

The FDA has placed a clinical hold on the study while Rocket works with trial monitors and experts to investigate the cause of the patient’s death.

By Ned Pagliarulo • May 27, 2025

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

GlycoEra raises $130M, riding interest in protein degraders

The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach drug targets other technologies can’t.

By Gwendolyn Wu • May 27, 2025

The transformative impact of integrated informatics platforms on biopharma R&D

Integrated informatics platforms boost R&D speed, data quality and ROI across BioPharma

By Nicola Brookman-Amissah, PhD • May 27, 2025

Novo pressures GLP-1 compounders as FDA ban takes hold

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off versions that have dented its sales forecasts.

By Kristin Jensen • May 22, 2025

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K. regulators cleared Sarepta to restart an Elevidys study and Altos Labs bought a startup.

By BioPharma Dive staff • May 22, 2025

Reproductive health startup raises $65M for infertility drugs

Founded in 2021, ReproNovo has licensed rights to two drugs from Mereo BioPharma and ObsEva that it thinks could address fertility issues in men and women.

By Delilah Alvarado • May 21, 2025

Moderna pulls application for combo COVID, flu shot

The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from yesterday.

By Delilah Alvarado • May 21, 2025

Roche strikes second Orionis deal to develop ‘molecular glues’ for cancer

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body of destructive proteins that are hard to target by other means.

By Kristin Jensen • May 21, 2025

Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff

Tourmaline Bio disclosed results for a potential rival to a Novo Nordisk drug. Elsewhere, data emerged for a psychedelic and CRISPR Therapeutics expanded its toolkit.

By BioPharma Dive staff • May 20, 2025

Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot

CEO Keith Gottesdiener will be replaced by Prime's CFO as the company cuts 25% of its workforce and deprioritizes its lead program.

By Gwendolyn Wu • May 19, 2025

Novavax’s COVID vaccine gets FDA approval, but with limits

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the company.

By Delilah Alvarado • May 19, 2025

Regeneron wins bid to buy 23andMe out of bankruptcy

The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.

By Ned Pagliarulo • May 19, 2025

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and the FDA scheduled an advisory meeting.

By Ben Fidler • May 16, 2025

A bespoke CRISPR therapy suggests a blueprint for treating ‘N-of-1’ diseases

A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design and test a new CRISPR medicine in just a few months. 

By Ben Fidler • May 15, 2025

FDA delays approval decision for Biohaven rare disease drug

Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an outside group of advisers to evaluate it as well.

By Jacob Bell • May 15, 2025

AbbVie stakes $335M on a startup’s RNAi drugs

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including neurology, immunology and cancer. 

By Gwendolyn Wu • May 15, 2025

GSK to buy liver disease drug for $1.2B

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver disease franchise.

By Kristin Jensen • May 14, 2025

Bluebird extends deal deadline; Affimed files for insolvency

Shareholders in Bluebird now have a choice of two offers from would-be acquirers Carlyle and SK Capital. Elsewhere, Cytokinetics shared more aficamten data and BridgeBio started a new kind of Attruby trial.

By BioPharma Dive staff • May 14, 2025

Galapagos backtracks on planned split

Having now appointed Henry Gosebruch as CEO of the intact company, Galapagos says its priorities are exploring strategic options and “transformative” deals.

By Jacob Bell • May 13, 2025

iTeos, GSK to shelve TIGIT drug after study setback

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic review in response. 

By Ben Fidler • May 13, 2025

FDA follows EMA in limiting use of Valneva shot

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and now the U.S. to suspend use in older adults pending an investigation.

By Delilah Alvarado • May 12, 2025

Innovating a healthier tomorrow: Entering a new era of medicine

Explore the cutting-edge of science and learn how Danaher is advancing healthcare innovation

May 12, 2025

Eli Lilly extends Purdue alliance; EMA investigates Valneva shot

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

By BioPharma Dive staff • May 9, 2025

4 more biotechs cut staff amid market tumult

Vor Bio, Korro Bio, Insitro and Rallybio revealed plans to lay off chunks of their respective workforces in the latest job cuts for a sector struggling to hold its financial footing. 

By Ben Fidler • May 8, 2025